Neurocrine Biosciences Stock News

Late Monday, Neurocrine Biosciences reported second-quarter earnings that doubled the year-earlier figure, shattering analyst expectations and sending shares of NBIX stock higher after hours.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2020 and provided revised full-year 2020 financial expense guidance.

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 17.1% during the second quarter, according to its most recent disclosure with the

The United States must counter the rise of China with a stronger military and a renewal of the U.S. economy.

Vident Investment Advisory LLC grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 58.9% during the 2nd quarter, according to the company in its most recent 13F filing with th

Janney Montgomery Scott LLC increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commi

The Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market will grow by USD 909.86 mn during 2020-2024

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday, August 6, 2020. Kyle Gano, Chief Business Development and

The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by Mizuho from $105.00 to $127.00 in a report released on Thursday morning, The Fly reports. The brokerage currently has a neutral

A unique opportunity has developed for investors looking for a biotech to add to their portfolio. I will explain why the recent Cilag Holding decision has been misconstrued by some investors.

Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, and continues to strengthen, amid recently receding volatility, writes...

Health-care stocks keep hitting highs. Mark Newton of Newton Advisors and Danielle Shay of Simpler Trading share their favorite names.